Mirae Asset Capital Life Science, Inc.Firm match from fund name (lower confidence)
Mirae Asset BioHealth Ingenuity Fund I, LP
Open, writing first checksEmerging manager
Open: first sale Jan 2026, per Form D (fund age approximates vintage)
- Vintage
- 2026
- Fund size
- $5.37M (Form D)
- Stages
- Not stated
- Sectors
- Healthtech, Biotech
- Regions
- Not stated
01 · Thesis
Mirae Asset Capital Life Science invests in life science companies, mainly Series A and B stage businesses entering the clinic. It focuses on oncology, immunology, CV/metabolic, CNS/ophthalmology, and rare genetic disease, prioritizing small molecules, biologics, and nucleic acid therapeutics.Inferred from the firm's website
02 · Initial check
$54K to $89K (estimated from fund size)
Estimated from Form D
03 · Who to approach
Named on this fund's Form D
- Young Hwan Kim, President of the Manager of the General Partner of the Issuer.
04 · Deals
No deals attributed to this fund yet.
05 · Evidence
No quoted evidence from the firm's website yet.
06 · Sources
Last verified: Oct 28, 2026